Biotech's Positive Results
Executive Summary
Everyone else may be talking about discovery-based biotechs, but the fact is, top-rated Goldman Sachs biotech analyst Maykin Ho told the February 6 Mayfield/Wilson Sonsini conference, "Financing the Biopharmaceutical Company," biotechs with clinical-stage products aren't doing badly.